Clinical Trials Logo

Cardiomyopathy, Secondary clinical trials

View clinical trials related to Cardiomyopathy, Secondary.

Filter by:
  • None
  • Page 1

NCT ID: NCT05445323 Recruiting - Friedreich Ataxia Clinical Trials

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

Start date: August 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy. The study will evaluate up to three doses of single administration of LX2006 (AAVrh.10hFXN), an adeno-associated virus (AAV) gene therapy designed to intravenously deliver the human frataxin (hFXN) gene to cardiac cells over a 52-week period. Long-term safety and efficacy will be evaluated for an additional 4-years for a total of 5-years post LX2006 treatment.

NCT ID: NCT02960256 Completed - Sepsis Clinical Trials

The Impact of Infectious Disease on QT Segment

Start date: December 2016
Phase: N/A
Study type: Observational

Sepsis related to the development of cardiac complications. However, the investigators understanding regarding this condition remains incomplete. Possible explanations raised include coronary perfusion decrease, activation of the coagulation system and release of inflammatory mediators, including endotoxins, cytokines and others. In this study the investigators wanted to examine the impact of any infectious disease, (not necessarily Pneumonia), on the QT interval in patients hospitalized for acute infectious disease.